Next Article in Journal
Anti-Wrinkle Benefits of Peptides Complex Stimulating Skin Basement Membrane Proteins Expression
Next Article in Special Issue
Omega-3 Versus Omega-6 Polyunsaturated Fatty Acids in the Prevention and Treatment of Inflammatory Skin Diseases
Previous Article in Journal
Synthetic Human β Defensin-3-C15 Peptide in Endodontics: Potential Therapeutic Agent in Streptococcus gordonii Lipoprotein-Stimulated Human Dental Pulp-Derived Cells
Previous Article in Special Issue
The Omega-3 Fatty Acids EPA and DHA, as a Part of a Murine High-Fat Diet, Reduced Lipid Accumulation in Brown and White Adipose Tissues
Open AccessArticle

Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer’s Disease

1
Department of Physiology, School of Biology, Biomedical Research Institute of Murcia (IMIB-Arrixaca-UMU), University of Murcia, 30100 Murcia, Spain
2
Dementias´Unit, University Clinical Hospital “Virgen de la Arrixaca”, 30120 Murcia, Spain
3
Department of Biochemistry and Molecular Biology B and Immunology, Faculty of Medicine, Biomedical Research Institute of Murcia (IMIB-Arrixaca-UMU), University of Murcia, 30120 Murcia, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(1), 70; https://doi.org/10.3390/ijms21010070
Received: 18 October 2019 / Revised: 13 December 2019 / Accepted: 17 December 2019 / Published: 20 December 2019
(This article belongs to the Special Issue Omega-3 Fatty Acids in Health and Disease: New Knowledge 2019)
The protein Major Facilitator Superfamily Domain containing 2A (MFSD2a) was recently described as the primary carrier for docosahexaenoic acid (DHA) into the brain. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by lower DHA levels in blood lipids. The aim of this study was to investigate the expression of MFSD2a in the whole blood and brain as a potential biomarker of AD. Three groups were established: 38 healthy controls, 48 subjects with moderate AD (GDS4), and 47 with severe AD (GDS6). We analyzed postmortem brain samples from the hippocampus of 11 healthy controls and 11 severe AD patients. Fatty acid (FA) was determined in serum and brain by gas chromatography. Blood and brain MFSD2a protein expression was analyzed by Western blotting. We found a significant and progressive decline of MFSD2a levels in blood of AD patients (Control 0.83 ± 0.13, GDS4 0.72 ± 0.09, GDS6 0.48 ± 0.05*, p ˂ 0.01). We also corroborated a significant reduction of DHA and other n-3 long-chain polyunsaturated FA in serum of AD. No differences were found in MFSD2a expression or FA levels in brain of controls and AD subjects. MFSD2A carrier was analyzed in AD patients for the first time and the level of MFSD2a in the whole blood could be a potential biomarker of this disease. View Full-Text
Keywords: aging; neurologic disorders; omega-3 PUFA; MFSD2a carrier; Alzheimer’s disease aging; neurologic disorders; omega-3 PUFA; MFSD2a carrier; Alzheimer’s disease
Show Figures

Figure 1

MDPI and ACS Style

Sánchez-Campillo, M.; Ruiz-Pastor, M.J.; Gázquez, A.; Marín-Muñoz, J.; Noguera-Perea, F.; Ruiz-Alcaraz, A.J.; Manzanares-Sánchez, S.; Antúnez, C.; Larqué, E. Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, 70.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop